Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Location status: Recruiting
Location contact
Electra D. Paskett, PhD
CONTACT
Electra D. Paskett, PhD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06314672
This clinical trial tests the impact of the The Ohio State University Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) project on clinical trial referrals and enrollment in racial/ethnic minorities. Progress in cancer prevention, detection and treatment can only be made by identifying and validating new and improved methods, compounds and modalities in clinical trials. Unfortunately, participation in clinical trials is not equal across all racial and ethnic groups, limiting progress against cancer in all population groups and further widening the disparity gap. To change this picture, concerted effort needs to be directed both at the communities at risk for being left out of trials and the systems that cause the disparities at all levels involved in accrual to clinical trials. The CUSP2CT project may have the potential to increase referral and accrual of racial/ethnic minorities to prevention/control and treatment trials.
Interested in participating?
Request InfoAll sexes
Interventional
Not applicable
Columbus, Ohio, 43210, United States
Location status: Recruiting
Electra D. Paskett, PhD
CONTACT
Electra D. Paskett, PhD
PRINCIPAL_INVESTIGATOR
PRIMARY OBJECTIVES:
I. Conduct a baseline assessment of referral patterns and accrual of racial and ethnic minorities to clinical trials at Ohio State University Comprehensive Cancer Center (OSUCCC) by cancer disease group (breast, gastrointestinal, genitourinary, thoracic, hematologic,and others) and examine factors at the system (i.e., eligible clinical trial protocol, clinic context and culture), provider (trial discussed with patient) and patient levels (agreed or refused participation) that influence referral and accrual. (Phase I) II. Implement a multi-level intervention in a stepped wedge design in referral in 10 counties in the OSUCCC catchment area using the Accrual to Clinical Trials framework. (Phase II) III. Evaluate the impact of the intervention on referral (primary outcome) and accrual (secondary outcomes) to clinical trials. (Phase III)
OUTLINE: Counties are cluster randomized to 1 of 3 steps in Phase II of the study.
PHASE I (DEVELOPMENT): Community members, clinic staff, and providers undergo in-depth interview for intervention development on study. Researchers review baseline data on referral patterns and accrual of racial and ethnic minorities to clinical trials in each clinic site. Providers, clinical staff, and research team participate in implementation discussion. Accrual enhancement program (AEP) strategies developed and initiated in one OSUCCC/James clinic. Providers and community members participate in educational sessions on study. (Year 1)
PHASE II (IMPLEMENTATION): Participants participate in the AEP in the remaining clinics at OSUCCC/James and community clinics on study. Community members and providers participate in culturally tailored educational activities. Providers, patients, and community members participate in interviews to explore current barriers to referral and participation on study. (Years 2-4)
PHASE III (EVALUATION): Providers, clinic staff, patients, and community members participate in interviews to explore current barriers to referral and participation. (Year 5)
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Participate in AEP
Participate in implementation discussions
Other names: Discuss
Participate in educational sessions/activities
Undergo interview
Undergo data capture review
Ancillary studies
Time frame: Baseline to 24 months
Calculate change in clinical trial referrals
Time frame: Baseline to 24 months
Calculate the change in clinical trial minority enrollments
Time frame: Baseline to 24 months
Calculate accrual and retention rates
Time frame: Up to 24 months
Define gaps in trial accrual
Time frame: Up to 24 months
Calculate the number of clinics who adapt program
Time frame: Up to 24 months
Recent regression models used for stepped wedge designs that flexibly model the effect curve of the intervention over time. Effect estimates and 95% confidence intervals will accompany significance tests, and graphical displays of the final effect curve will aid in understanding the efficacy of the intervention.
Contact information is provided by the study sponsor or research team.
Ohio State University Comprehensive Cancer Center
Other
The Ohio State University Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) Project
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04494945
Adenocarcinoma, Adnexal Diseases
Portland, Oregon, United States
View Trial DetailsNCT06015932
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Rochester, Minnesota, United States
View Trial DetailsNCT06246955
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Scottsdale, Arizona, United States
View Trial DetailsNCT06198010
Hematopoietic and Lymphatic System Neoplasm, Hematopoietic and Lymphoid System Neoplasm
Scottsdale, Arizona, United States
View Trial Details